IRVING, Texas, Dec. 17, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, has been granted a patent in The People's Republic of China covering its molecular profiling service, Caris Molecular Intelligence™, for cancer patients. China represents a large population of unmet medical need, with approximately 3.5 million people diagnosed with cancer each year, according to the nation's National Cancer Registry, and high mortality rates for those suffering from the disease (approximately 2.5 million people die of cancer annually in China).
This most recent granted patent comprises a robust, growing international patent portfolio for Caris in molecular diagnostics, which also includes granted patents covering tumor molecular profiling in Singapore and South Africa. The company's tumor profiling patent filings were among some of the earliest in cancer personalized diagnostics, dating back to 2006. In fact, Caris has one of the first issued patents for individualized treatment selection for cancer.
"The purpose of patents is to spur and reward innovation, which in the molecular diagnostics industry in particular, drives continual improvement to help patients realize better treatment outcomes," said David D. Halbert, Chairman and Chief Executive Officer at Caris Life Sciences. "Through our strong, global patent portfolio, Caris remains committed to our role as industry-leading innovators in personalized medicine."
In total, the company's entire patent portfolio for assessing cancer currently includes 27 domestic and international awards for both Molecular Intelligence™ and Carisome™, the company's in-development blood-based diagnostic platform
|SOURCE Caris Life Sciences|
Copyright©2012 PR Newswire.
All rights reserved